Suppr超能文献

基于完整重组酿酒酵母细胞的疫苗。

Vaccines based on whole recombinant Saccharomyces cerevisiae cells.

机构信息

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

FEMS Yeast Res. 2010 Dec;10(8):1060-9. doi: 10.1111/j.1567-1364.2010.00665.x.

Abstract

The ultimate goal of therapeutic vaccines is to activate and exploit the patient's own immune system to vigorously and dynamically seek and eradicate established malignant or virally infected cells. Therapeutic vaccines also offer the potential for preventing disease recurrence. Saccharomyces cerevisiae-based vaccines, where the yeast is engineered to express viral or tumor antigens, represent an ideal therapeutic approach due to their ability to stimulate tumor- or viral-specific CD4(+) and CD8(+) T-cell responses that are capable of reducing disease burden. This review describes preclinical and clinical studies supporting the development of S. cerevisiae-based therapeutic vaccines for the treatment of cancer and viral diseases, as well as multimodal strategies in which therapeutic vaccines are combined with cytotoxic drugs to achieve a greater clinical response.

摘要

治疗性疫苗的最终目标是激活和利用患者自身的免疫系统,积极主动地寻找并清除已建立的恶性或病毒感染细胞。治疗性疫苗还有预防疾病复发的潜力。基于酿酒酵母的疫苗通过工程改造使酵母表达病毒或肿瘤抗原,由于其能够刺激肿瘤或病毒特异性 CD4(+)和 CD8(+)T 细胞反应,从而降低疾病负担,因此代表了一种理想的治疗方法。本综述描述了支持开发基于酿酒酵母的治疗性疫苗治疗癌症和病毒疾病的临床前和临床研究,以及将治疗性疫苗与细胞毒性药物联合使用以实现更大临床反应的多模态策略。

相似文献

1
Vaccines based on whole recombinant Saccharomyces cerevisiae cells.
FEMS Yeast Res. 2010 Dec;10(8):1060-9. doi: 10.1111/j.1567-1364.2010.00665.x.
5
Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
Exp Dermatol. 2007 Oct;16(10):814-22. doi: 10.1111/j.1600-0625.2007.00599.x.
6
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x.
7
Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Eur J Immunol. 2008 Jul;38(7):1867-76. doi: 10.1002/eji.200737923.
8
Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
mBio. 2021 Aug 31;12(4):e0201821. doi: 10.1128/mBio.02018-21. Epub 2021 Aug 17.
9
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol Immunother. 2014 Mar;63(3):225-34. doi: 10.1007/s00262-013-1505-8. Epub 2013 Dec 7.
10
Inducing efficient cross-priming using antigen-coated yeast particles.
J Immunother. 2008 Sep;31(7):607-19. doi: 10.1097/CJI.0b013e318181c87f.

引用本文的文献

1
Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.
Am J Respir Crit Care Med. 2025 Jun;211(6):1007-1017. doi: 10.1164/rccm.202410-2076OC.
2
Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy.
Hum Vaccin Immunother. 2025 Dec;21(1):2469416. doi: 10.1080/21645515.2025.2469416. Epub 2025 Mar 24.
3
Establishment of an in vitro evaluation method for immunomodulatory functions of yeast strains.
Anal Sci. 2024 Nov;40(11):2043-2051. doi: 10.1007/s44211-024-00641-4. Epub 2024 Aug 3.
5
New Trends in Vaccine Characterization, Formulations, and Development.
Vaccines (Basel). 2024 Mar 20;12(3):338. doi: 10.3390/vaccines12030338.
8
Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.
J Fungi (Basel). 2023 May 31;9(6):633. doi: 10.3390/jof9060633.
10
Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines.
Pharmaceutics. 2022 Dec 14;14(12):2792. doi: 10.3390/pharmaceutics14122792.

本文引用的文献

2
Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence.
Immunol Res. 2010 Jul;47(1-3):216-27. doi: 10.1007/s12026-009-8152-3.
5
Hepatitis C virus infection and immunomodulatory therapies.
Clin Liver Dis. 2009 Aug;13(3):391-401. doi: 10.1016/j.cld.2009.05.007.
6
Enhancing immune responses to tumor-associated antigens.
Cancer Biol Ther. 2009 Aug;8(15):1440-9. doi: 10.4161/cbt.8.15.9133. Epub 2009 Aug 1.
10
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine. 2008 Aug 19;26 Suppl 10(Suppl 10):K53-61. doi: 10.1016/j.vaccine.2008.06.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验